Tricida, Inc. (NASDAQ:TCDA) Sees Significant Drop in Short Interest
Tricida, Inc. (NASDAQ:TCDA) Sees Significant Drop in Short Interest
Tricida, Inc. (NASDAQ:TCDA – Get Rating) saw a significant decline in short interest in the month of December. As of December 15th, there was short interest totalling 10,820,000 shares, a decline of 22.7% from the November 30th total of 14,000,000 shares. Approximately 28.4% of the company's shares are short sold. Based on an average daily volume of 11,330,000 shares, the days-to-cover ratio is currently 1.0 days.
Tricida，Inc.(纳斯达克代码：TCDA-GET Rating)12月份空头股数业务大幅下滑。截至12月15日，空头股数共有1082万股，比11月30日1400万股的总数下降了22.7%。该公司约28.4%的股票被卖空。以日均成交量11,330,000股计算，目前天数与回补比率为1.0天。
Tricida Stock Down 11.9 %
Tricida股价下跌11.9%
Shares of NASDAQ TCDA traded down $0.02 during trading hours on Friday, reaching $0.15. The stock had a trading volume of 3,212,580 shares, compared to its average volume of 6,092,721. Tricida has a fifty-two week low of $0.13 and a fifty-two week high of $13.85. The firm has a 50-day moving average of $0.25 and a 200-day moving average of $7.23.
上周五交易时段，纳斯达克天猫的股价下跌0.02美元，至0.15美元。该股成交量为3,212,580股，而其平均成交量为6,092,721股。Tricida的价格为0.13美元，为52周低点，52周高点为13.85美元。该公司的50日移动均线切入位在0.25美元，200日移动均线切入位在7.23美元。
Tricida (NASDAQ:TCDA – Get Rating) last announced its earnings results on Monday, November 14th. The company reported ($0.44) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.54) by $0.10. Equities research analysts forecast that Tricida will post -1.88 earnings per share for the current year.
Tricida(纳斯达克代码：TCDA-GET Rating)最近一次公布财报是在11月14日(星期一)。该公司公布本季度每股收益(EPS)为0.44美元，比分析师普遍预期的0.54美元高出0.10美元。股票研究分析师预测，Tricida本年度每股收益将达到1.88美元。
Insider Buying and Selling at Tricida
Tricida的内幕买卖
Institutional Trading of Tricida
Tricida的机构交易
Large investors have recently made changes to their positions in the company. VR Adviser LLC raised its stake in Tricida by 26.9% during the 3rd quarter. VR Adviser LLC now owns 9,050,064 shares of the company's stock valued at $94,845,000 after acquiring an additional 1,917,985 shares during the last quarter. BlackRock Inc. raised its stake in Tricida by 37.6% during the 3rd quarter. BlackRock Inc. now owns 3,698,400 shares of the company's stock valued at $38,759,000 after acquiring an additional 1,009,907 shares during the last quarter. Deep Track Capital LP raised its stake in Tricida by 13.6% during the 1st quarter. Deep Track Capital LP now owns 2,652,693 shares of the company's stock valued at $21,805,000 after acquiring an additional 317,550 shares during the last quarter. Frazier Life Sciences Management L.P. purchased a new stake in Tricida during the 1st quarter valued at approximately $17,115,000. Finally, Commodore Capital LP raised its stake in Tricida by 16.3% during the 2nd quarter. Commodore Capital LP now owns 2,028,453 shares of the company's stock valued at $19,635,000 after acquiring an additional 283,883 shares during the last quarter.
大型投资者最近对他们在该公司的头寸进行了调整。VR咨询公司LLC在第三季度增持了26.9%的Tricida股份。VR Adviser LLC在上个季度增持了1,917,985股后，现在拥有9,050,064股公司股票，价值94,845,000美元。贝莱德股份有限公司在第三季度增持了37.6%的天合光能股份。贝莱德股份有限公司在上个季度增持了1,009,907股后，目前持有该公司3,698,400股股票，价值38,759,000美元。第一季度，Deep Track Capital LP将其在Tricida的持股比例提高了13.6%。在上个季度增持了317,550股后，Deep Track Capital LP现在拥有该公司2,652,693股股票，价值21,805,000美元。弗雷泽生命科学管理公司在第一季度购买了Tricida的新股份，价值约17,115,000美元。最后，Commodore Capital LP在第二季度将其在Tricida的持股增加了16.3%。Commodore Capital LP在上个季度额外收购了283,883股后，现在拥有该公司2,028,453股股票，价值19,635,000美元。
Analysts Set New Price Targets
分析师设定新的价格目标
Several research analysts recently commented on TCDA shares. Needham & Company LLC cut Tricida from a "buy" rating to a "hold" rating in a research note on Tuesday, October 25th. Cowen cut Tricida from an "outperform" rating to a "market perform" rating in a research note on Monday, October 24th. JPMorgan Chase & Co. cut Tricida from a "neutral" rating to an "underweight" rating in a research note on Tuesday, October 25th. Finally, Cowen cut Tricida to a "market perform" rating in a research report on Monday, October 24th. One research analyst has rated the stock with a sell rating, three have issued a hold rating and one has assigned a buy rating to the company. According to data from MarketBeat, the company currently has an average rating of "Hold" and an average target price of $17.00.
几位研究分析师最近对TcdA股发表了评论。Needham&Company LLC在10月25日星期二的一份研究报告中将Tricida的评级从“买入”下调至“持有”。考恩在10月24日周一的一份研究报告中将Tricida的评级从“跑赢大盘”下调至“市场表现”。摩根大通在10月25日星期二的一份研究报告中将Tricida的评级从中性下调至减持。最后，考恩在10月24日星期一的一份研究报告中将Tricida的评级下调至“市场表现”。一位研究分析师对该股的评级为卖出，三位分析师给出了持有评级，一位分析师给出了该公司的买入评级。根据MarketBeat的数据，该公司目前的平均评级为持有，平均目标价为17.00美元。
About Tricida
关于Tricida
(Get Rating)
(获取评级)
Tricida, Inc operates as a pharmaceutical company. It focuses on the development and commercialization of veverimer (TRC101), a non-absorbed orally-administered polymer that has completed Phase III trial to treat metabolic acidosis in patients with chronic kidney disease by binding and removing acid from the gastrointestinal track.
Tricida，Inc.是一家制药公司。它的重点是Vvermer(TRC101)的开发和商业化，这是一种非吸收的口服聚合物，已经完成了第三阶段试验，通过结合和去除胃肠道中的酸来治疗慢性肾脏疾病患者的代谢性酸中毒。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Tricida (TCDA)
- MarketBeat: Week in Review 12/26 – 12/30
- The Dogs Of Tech: It's Time For A Bite Of These Stocks
- Does This Acquisition Make Microsoft a Bear Market Buy?
- Should You Warm up to Generac Stock for the Winter?
- Is Kintara Therapeutics A Hidden Gem?
- 免费获取StockNews.com关于Tricida的研究报告(TcdA)
- MarketBeat：回顾一周12/26-12/30
- 科技狗：是时候咬一口这些股票了
- 这笔收购会让微软成为熊市买入者吗？
- 你应该热身到Generac股票过冬吗？
- 金塔拉治疗公司是一颗隐藏的宝石吗？
Receive News & Ratings for Tricida Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tricida and related companies with MarketBeat.com's FREE daily email newsletter.
接受Tricida Daily的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对Tricida和相关公司的最新新闻和分析师评级的每日简要摘要。